Trobix Bio
Phage-based Antimicrobial Resistance-sensitizing Solutions
Company Overview
Snapshot
Founded in March 2019 by Adi Elkeles, Trobix Bio operates with 1–10 employees. The company has raised $8.2 million across 4 funding rounds from 2 investors. In March 2023, Trobix Bio secured funding from The Chartered Group to advance its precision microbiome oncology therapeutics.
Business overview
Trobix Bio is an Israeli biotech company focused on human microbiome research. The company utilizes its proprietary TBX™ technology platform, which integrates CRISPR, phage, and synthetic biology, to reprogram specific activities in targeted microbiome bacteria. This technology is applied to develop orally administered precision oncology therapeutics. Trobix Bio's preclinical products, TBX201 and TBX301, aim to mitigate severe diarrhea and colitis in cancer patients undergoing irinotecan or checkpoint inhibitor treatments, thereby improving treatment completion rates and patient quality of life. The company operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the global pharmaceuticals market.
Strategic signal
Trobix Bio's strategic focus on developing precision microbiome oncology therapeutics, as evidenced by its March 2023 funding from The Chartered Group, signals a continued investor interest in innovative biotech solutions for cancer treatment. This investment validates the potential of their TBX™ technology platform, which leverages CRISPR, phage, and synthetic biology, to address significant unmet medical needs in oncology by improving patient tolerance to therapies and expanding treatment options.
Log in to access full profile ›Company Intelligence Q&A
- What is Trobix Bio's primary focus?
- Trobix Bio is a biotech company focused on pioneering human microbiome solutions, utilizing CRISPR, phage, and synthetic biology to develop precision oncology therapeutics.
- When was Trobix Bio founded?
- Trobix Bio was founded in March 2019.
- Which investor participated in Trobix Bio's March 2023 funding round?
- In March 2023, Trobix Bio received funding from The Chartered Group to advance its precision microbiome oncology therapeutics.
- What is the status of Trobix Bio's operations?
- Trobix Bio is currently non-active and ceased to operate in September 2025.
- What are Trobix Bio's key preclinical products?
- Trobix Bio's key preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively.